Stockholm - Delayed Quote SEK

Ascelia Pharma AB (publ) (ACE.ST)

3.8550
+0.0600
+(1.58%)
At close: May 9 at 5:29:33 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Magnus O. Corfitzen Chief Executive Officer 3.87M -- 1975
Mr. Andreas Norlin Chief Scientific Officer -- -- 1970
Mr. Mikael Widell Head of IR & Communications -- -- 1958
Ms. Julie Waras Brogren Deputy CEO & Chief Commercial Officer -- -- 1972

Ascelia Pharma AB (publ)

Hyllie Boulevard 34
Malmö, 215 32
Sweden
46 7 35 17 91 18 https://www.ascelia.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
11

Description

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.

Corporate Governance

Ascelia Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 14, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC

Ascelia Pharma AB (publ) Earnings Date

Recent Events

Related Tickers

ELIC.ST Elicera Therapeutics AB (publ)
5.12
+16.36%
 
XSPRAY.ST Xspray Pharma AB (publ)
32.10
-8.29%
 
XBRANE.ST Xbrane Biopharma AB (publ)
0.2032
-1.26%
 
ONCO.ST Oncopeptides AB (publ)
1.8240
-2.88%
 
BINV.ST BioInvent International AB (publ)
32.60
-1.21%
 
ATORX.ST Alligator Bioscience AB (publ)
4.1500
+4.56%
 
HNSA.ST Hansa Biopharma AB (publ)
25.94
+1.33%
 
IMMU.ST Mendus AB (publ)
5.78
-3.51%
 
ACTI.ST Active Biotech AB (publ)
0.0908
-0.66%
 
CANTA.ST Cantargia AB (publ)
1.6300
+5.16%